Bevacizumab Biosimilars Market Report 2025

The bevacizumab biosimilars market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to patent expiry, cost containment in healthcare, increasing incidence of cancer, market competitiveness, patient access and affordability, biosimilar acceptance.

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for cancer therapies, biosimilar development expertise, healthcare system pressures, biosimilar regulatory landscape, biosimilar interchangeability. Major trends in the forecast period include collaborations and partnerships, regulatory advancements and approvals, biosimilar development and innovation, market access strategies, biosimilar lifecycle management.

The increasing incidence of cancer cases is anticipated to drive the growth of the bevacizumab biosimilars market in the future. Cancer incidence refers to the number of new cancer cases in a defined population over a specific period. Bevacizumab is a biologic that inhibits tumor angiogenesis, potentially leading to tumor shrinkage and growth inhibition. It is comparable to reference biologics in terms of efficacy and safety for treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2024, the UK's National Health Service (NHS) reported 346,217 new cancer diagnoses in 2022, averaging 948 cases per day. This marks a 5% increase from the 329,664 diagnoses in 2021. Additionally, cancer diagnoses saw a 7% rise, going from 167,917 to 180,877 in 2022. Consequently, the growing prevalence of cancer cases is driving the bevacizumab biosimilars market.

The rising healthcare expenditure is projected to drive the growth of the bevacizumab biosimilars market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services within a specific timeframe, typically expressed as a monetary value. The bevacizumab biosimilars play a significant role in influencing healthcare expenditure by providing cost-effective alternatives to the originator drug. For example, in 2022, the Office for National Statistics, a UK-based national statistical authority, reported that healthcare expenditure in the UK reached approximately £283 billion. This reflects a 0.7% increase in nominal terms compared to spending in 2021. Thus, the rise in healthcare expenditure is driving the bevacizumab biosimilars market.

Product innovation has become a prominent trend gaining traction in the bevacizumab biosimilars market. Key market players are strategically focusing on the development of inventive products to enhance their market positions. An illustrative example is the collaborative effort of Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, in May 2022, resulting in the launch of a biosimilar named Abevmy (bevacizumab). This biosimilar is designed to mirror Roche's Avastin (bevacizumab) and has received approval from Health Canada for application in four oncology indications. Abevmy boasts efficacy, safety, and quality comparable to the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF). This exemplifies the trend of product innovation as a strategic focus within the bevacizumab biosimilars market.

Leading companies in the bevacizumab biosimilars market are strategically engaging in collaborations to develop Next-Generation Biosimilars, a move aimed at fortifying and sustaining their market positions. Next-generation biosimilars contribute to the advancement of the bevacizumab biosimilars market through technological enhancements, improved manufacturing processes, and heightened therapeutic efficacy. A noteworthy example is the exclusive partnership formed in May 2022 between Prestige Biopharma, a Singapore-based pharmaceutical company, and Intas Pharmaceuticals, a multinational pharmaceutical company based in India. This collaboration focuses on Prestige's bevacizumab biosimilar, HD204, currently in Phase III development and designed to replicate Roche's Avastin for various cancers. The exclusive agreement covers key regions such as the US, Europe, and parts of Asia and Africa. With HD204 positioned to offer advancements in bevacizumab biosimilar technology, the collaboration allows Intas Pharmaceuticals to commercialize the biosimilar, leveraging its robust sales and marketing capabilities. This strategic alignment supports Prestige's broader goal of expanding market reach and providing affordable access to patients through its innovative bevacizumab production technology.

In November 2022, Biocon Biologics Ltd., an India-based firm and subsidiary of Biocon Ltd. engaged in the manufacturing of biopharmaceuticals, successfully acquired Viatris Inc.'s global biosimilars business for an undisclosed amount. This strategic acquisition is geared towards reinforcing Biocon Biologics' presence in the biosimilars market. Viatris Inc., based in the US, is a pharmaceutical and healthcare company specializing in medicines for major therapeutic areas, including cancer, with notable products such as Bevacizumab.

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA.

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bevacizumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bevacizumab biosimilars are a specific class of medications that closely resemble a reference biologic drug named bevacizumab. These biosimilars are designed to mimic the original drug's properties and are frequently utilized to impede the formation of new blood vessels within tumors. By inhibiting this process, they effectively decelerate the progression of tumors.

Bevacizumab biosimilar products, including Avastin, Mvasi, Zirabev, Aybintio, and similar alternatives, represent a range of anti-angiogenic therapies designed to impede new blood vessel formation. These products are accessible through diverse distribution channels such as hospital pharmacies, online platforms, and retail outlets. Their applications span across treating colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

The bevacizumab biosimilar market research report is one of a series of new reports that provides bevacizumab biosimilar market statistics, including bevacizumab biosimilar industry global market size, regional shares, competitors with a bevacizumab biosimilar market share, detailed bevacizumab biosimilar market segments, market trends, and opportunities, and any further data you may need to thrive in the bevacizumab biosimilar industry. This bevacizumab biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bevacizumab biosimilars market consists of sales of byvasda, cizumab, alymsys, bevax, and cyramza. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.